Stoke Therapeutics, Inc. — Director's Dealing 2019

Jun 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2019-06-19

Reporting Person: RTW INVESTMENTS, LP (10% Owner)
Reporting Person: WONG RODERICK (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-19	Common Shares	C	2799910	—	Acquired	2799910	Indirect
2019-06-19	Common Shares	P	555556	$18.00	Acquired	3355466	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-19	Class B Convertible Preferred	$	C	2799910	Disposed		Common Shares (2799910)	Indirect

Footnotes

F1: Each share of Class B Convertible Preferred converted into Common Shares, on a one-for-one basis, upon the closing of the Issuer's initial public offering, which occurred on June 19, 2019.

F2: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.